GenPath’s Hematopathology laboratory provides comprehensive diagnostic, prognostic and therapeutic information on a broad range of hematological disorders including MDS, CLL, and Myeloma.
One pathologist coordinates the case analysis integrating morphology, karyotyping, molecular and advanced Array CGH testing results. This ensures that all relevant diagnostic information is considered when making the final diagnosis. GenPath is only one of a few labs in the US that offers an extensive test menu in-house allowing for the entire patient workup to be completed at one laboratory location.
Testing Services
GenPath has developed a comprehensive set of test profiles and algorithms for our clients in order to optimize diagnostic and therapeutic testing and disease monitoring. These are published in the GenPath’s “Hematopathology Disease-State Reference Guide”. An oncologist can clearly follow how GenPath uniquely approaches each blood disorder
and the appropriate testing required to make a final diagnosis.
GenPath’s state-of-the-art offerings include Array CGH testing (GenArray) that scans a patient’s entire genome for chromosomal abnormalities. Our BCR/ABL is a quantitative RT-PCR assay that is best in class for the diagnosis and monitoring of CML patients.
More than 95% of all our cancer specific tests are performed in-house affording you quick turnaround times and accurate/reliable results. Our Lab is CLIA and CAP certified so you can trust that your tests are performed with the highest standards.
GenPath has pioneered the use of Array CGH in hematological malignancies. GenArray is a custom-design microarray that utilizes 64,000 DNA oligonucleotide probes to search the entire patient’s genome for chromosomal deletions or additions. Our limit of detection is an incredible 10%, a significant advantage over competitive CGH tests that average 30%.
Since introducing the GenArray in 2009 we have run more than 4,000 hematological Array cases in the disease states of MDS, Myeloma, and CLL.
GenArray provides key diagnostic/prognostic information across multiple disease states:
MDS: GenArray detects additional abnormalities not picked up by FISH and cytogenetics. Multiple chromosomal abnormalities is often a poor prognostic indicator for MDS.
AML: GenArray can further define the diagnosis by providing the exact genetic loss or addition.
Myeloma: GenArray detects hyperploidy in plasma cell myeloma patients conferring a favorable prognosis.
CLL: GenArray can detect abnormalities not picked up by FISH that have prognostic implications.
See how GenArray changed the diagnosis and consequently the therapy decision!
Specimen Requirement: 2mL Bone Marrow
TAT: 7 days
Subscribe to our e-Newsletters to get our new products, innovations and updates delivered to your inbox.
